Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy

被引：130
作者：
Thibodeau, Jacques [1 ]
Bourgeois-Daigneault, Marie-Claude [1 ]
Lapointe, Rejean [2 ,3 ]
机构：
[1] Univ Montreal, Dept Microbiol & Immunol, Lab Immunol Mol, Montreal, PQ H3C 3J7, Canada
[2] Univ Montreal, Notre Dame Hosp, CRCHUM, Montreal, PQ H3C 3J7, Canada
[3] Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada
来源：
ONCOIMMUNOLOGY | 2012年 / 1卷 / 06期
基金：
加拿大健康研究院;
关键词：
cancer; HLA; immunotherapy; MHC Class II; tumor; vaccine; CD4(+) T-CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; INVARIANT CHAIN; HLA-DR; TUMOR-CELLS; METASTATIC MELANOMA; IMMUNE-RESPONSE; B-CELLS; EXPRESSION; CIITA;
D O I：
10.4161/onci.21205
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The success of immunotherapy relies on the participation of all arms of the immune system and the role of CD4(+) T lymphocytes in preventing tumor growth is now well established. Understanding how tumors evade immune responses holds the key to the development of cancer immunotherapies. In this review, we discuss how MHC Class II expression varies in cancer cells and how this influences antitumor immune responses. We also discuss the means that are currently available for harnessing the MHC Class II antigen presentation pathway for the development of efficient vaccines to activate the immune system against cancer.
引用
收藏
页码：908 / 916
页数：9
相关论文
共 86 条
[1]   The role of H2-O and HLA-DO in major histocompatibility complex class II-restricted antigen processing and presentation [J].
Alfonso, C ;
Liljedahl, M ;
Winqvist, O ;
Surh, CD ;
Peterson, PA ;
Fung-Leung, WP ;
Karlsson, L .
IMMUNOLOGICAL REVIEWS, 1999, 172 :255-266
[2]  
Almåsbak H, 2010, METHODS MOL BIOL, V629, P451, DOI 10.1007/978-1-60761-657-3_28
[3]   Tumor Vaccines for Breast Cancer [J].
Anderson, Karen S. .
CANCER INVESTIGATION, 2009, 27 (04) :361-368
[4]   Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity [J].
Armstrong, TD ;
Clements, VK ;
Martin, BK ;
Ting, JPY ;
OstrandRosenberg, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6886-6891
[5]   LONG-TERM HUMAN B-CELL LINES DEPENDENT ON INTERLEUKIN-4 AND ANTIBODY TO CD40 [J].
BANCHEREAU, J ;
DEPAOLI, P ;
VALLE, A ;
GARCIA, E ;
ROUSSET, F .
SCIENCE, 1991, 251 (4989) :70-72
[6]   Class II transactivator (CIITA) isoform expression and activity in melanoma [J].
Baton, F ;
Deruyffelaere, C ;
Chapin, M ;
Prod'homme, T ;
Charron, D ;
Al-Daccak, R ;
Alcaide-Loridan, C .
MELANOMA RESEARCH, 2004, 14 (06) :453-461
[7]   Integrated genomic analyses of ovarian carcinoma [J].
Bell, D. ;
Berchuck, A. ;
Birrer, M. ;
Chien, J. ;
Cramer, D. W. ;
Dao, F. ;
Dhir, R. ;
DiSaia, P. ;
Gabra, H. ;
Glenn, P. ;
Godwin, A. K. ;
Gross, J. ;
Hartmann, L. ;
Huang, M. ;
Huntsman, D. G. ;
Iacocca, M. ;
Imielinski, M. ;
Kalloger, S. ;
Karlan, B. Y. ;
Levine, D. A. ;
Mills, G. B. ;
Morrison, C. ;
Mutch, D. ;
Olvera, N. ;
Orsulic, S. ;
Park, K. ;
Petrelli, N. ;
Rabeno, B. ;
Rader, J. S. ;
Sikic, B. I. ;
Smith-McCune, K. ;
Sood, A. K. ;
Bowtell, D. ;
Penny, R. ;
Testa, J. R. ;
Chang, K. ;
Dinh, H. H. ;
Drummond, J. A. ;
Fowler, G. ;
Gunaratne, P. ;
Hawes, A. C. ;
Kovar, C. L. ;
Lewis, L. R. ;
Morgan, M. B. ;
Newsham, I. F. ;
Santibanez, J. ;
Reid, J. G. ;
Trevino, L. R. ;
Wu, Y. -Q. ;
Wang, M. .
NATURE, 2011, 474 (7353) :609-615
[8]   Transpeptidation and reverse proteolysis and their consequences for immunity [J].
Berkers, Celia R. ;
de Jong, Annemieke ;
Ovaa, Huib ;
Rodenko, Boris .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (01) :66-71
[9]   The prognostic impact of anti-cancer immune response: a novel classification of cancer patients [J].
Bindea, Gabriela ;
Mlecnik, Bernhard ;
Fridman, Wolf-Herman ;
Galon, Jerome .
SEMINARS IN IMMUNOPATHOLOGY, 2011, 33 (04) :335-340
[10]   Cellular responses to interferon-gamma [J].
Boehm, U ;
Klamp, T ;
Groot, M ;
Howard, JC .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :749-795
123456789